NRIX

Over the past six months, Nurix Therapeutics' stock price increased by 194.35% to $25.52 as of September 14, 2026. Key events include a major global collaboration with Roche for bexobrutideg in June 2026, valued at up to $2.3 billion with a $700 million upfront payment, which caused a premarket surge. In August 2026, Nurix received a $10 million milestone payment from Sanofi for the initiation of a Phase 1 trial for SAR448272/NX-3911. Q2 2026 financial results, reported on July 9, 2026, showed an EPS of -$0.81 and revenue of $9.04 million, both missing estimates, leading to a 6.6% stock decline. The company presented updated positive Phase 1a/b results for bexobrutideg in relapsed/refractory CLL/SLL and new preclinical data for chronic spontaneous urticaria. Nurix management participated in several investor conferences in September 2026, and Wes Burwell was appointed Chief Human Resources Officer in August 2026.